126 related articles for article (PubMed ID: 36444691)
1. NCALD as a potential predictive biomarker for the efficacy of platinum-based chemotherapy in ovarian cancer.
Konrad SM; Schwamborn K; Krüger A; Honert K; Schmitt M; Hellmann D; Schmalfeldt B; Meindl A; Kiechle M; Quante AS; Brambs C; Grill S; Ramser J
Biomark Med; 2022 Oct; 16(14):1029-1041. PubMed ID: 36444691
[No Abstract] [Full Text] [Related]
2. Low expression of NCALD is associated with chemotherapy resistance and poor prognosis in epithelial ovarian cancer.
Feng LY; Li L
J Ovarian Res; 2020 Mar; 13(1):35. PubMed ID: 32228639
[TBL] [Abstract][Full Text] [Related]
3. NCALD affects drug resistance and prognosis by acting as a ceRNA of CX3CL1 in ovarian cancer.
Dong C; Yin F; Zhu D; Cai X; Chen C; Liu X
J Cell Biochem; 2020 Nov; 121(11):4470-4483. PubMed ID: 32030795
[TBL] [Abstract][Full Text] [Related]
4. Upregulation of CALD1 predicted a poor prognosis for platinum-treated ovarian cancer and revealed it as a potential therapeutic resistance target.
Li W; Huang L; Qi N; Zhang Q; Qin Z
BMC Genomics; 2024 Feb; 25(1):183. PubMed ID: 38365611
[TBL] [Abstract][Full Text] [Related]
5. High NCALD expression predicts poor prognosis of cytogenetic normal acute myeloid leukemia.
Song Y; Zhang W; He X; Liu X; Yang P; Wang J; Hu K; Liu W; Zhang X; Jing H; Yuan X
J Transl Med; 2019 May; 17(1):166. PubMed ID: 31109331
[TBL] [Abstract][Full Text] [Related]
6. Association of UBE2L6 and ABCB6 Expression With Platinum Resistance in Serous Ovarian Carcinoma.
Shibahara M; Kurita T; Murakami M; Harada H; Koi C; Izumi H; Yoshino K
Anticancer Res; 2023 Aug; 43(8):3787-3792. PubMed ID: 37500176
[TBL] [Abstract][Full Text] [Related]
7. Abnormal methylation characteristics predict chemoresistance and poor prognosis in advanced high-grade serous ovarian cancer.
Feng LY; Yan BB; Huang YZ; Li L
Clin Epigenetics; 2021 Jul; 13(1):141. PubMed ID: 34289901
[TBL] [Abstract][Full Text] [Related]
8. Downregulation of RIF1 Enhances Sensitivity to Platinum-Based Chemotherapy in Epithelial Ovarian Cancer (EOC) by Regulating Nucleotide Excision Repair (NER) Pathway.
Liu YB; Mei Y; Tian ZW; Long J; Luo CH; Zhou HH
Cell Physiol Biochem; 2018; 46(5):1971-1984. PubMed ID: 29719287
[TBL] [Abstract][Full Text] [Related]
9. The EMT-activator ZEB1 is unrelated to platinum drug resistance in ovarian cancer but is predictive of survival.
Rae S; Spillane C; Blackshields G; Madden SF; Keenan J; Stordal B
Hum Cell; 2022 Sep; 35(5):1547-1559. PubMed ID: 35794446
[TBL] [Abstract][Full Text] [Related]
10. Interferon regulatory factor 1 is an independent predictor of platinum resistance and survival in high-grade serous ovarian carcinoma.
Cohen S; Mosig R; Moshier E; Pereira E; Rahaman J; Prasad-Hayes M; Halpert R; Billaud JN; Dottino P; Martignetti JA
Gynecol Oncol; 2014 Sep; 134(3):591-8. PubMed ID: 24995581
[TBL] [Abstract][Full Text] [Related]
11. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.
Tian H; Yan L; Xiao-Fei L; Hai-Yan S; Juan C; Shan K
Clin Epigenetics; 2019 Oct; 11(1):153. PubMed ID: 31666131
[TBL] [Abstract][Full Text] [Related]
12. The effects of REG4 expression on chemoresistance of ovarian cancer.
Xiang LW; Xue H; Ha MW; Yu DY; Xiao LJ; Zheng HC
J Obstet Gynaecol; 2022 Oct; 42(7):3149-3157. PubMed ID: 35929918
[TBL] [Abstract][Full Text] [Related]
13. Combination of Niraparib, Cisplatin and Twist Knockdown in Cisplatin-Resistant Ovarian Cancer Cells Potentially Enhances Synthetic Lethality through ER-Stress Mediated Mitochondrial Apoptosis Pathway.
Bahar E; Kim JY; Kim DC; Kim HS; Yoon H
Int J Mol Sci; 2021 Apr; 22(8):. PubMed ID: 33920140
[TBL] [Abstract][Full Text] [Related]
14. Metabolic modulation of CtBP dimeric status impacts the repression of DNA damage repair genes and the platinum sensitivity of ovarian cancer.
Li J; Wang Y; Wang L; Hao D; Li P; Su M; Zhao Z; Liu T; Tai L; Lu J; Di LJ
Int J Biol Sci; 2023; 19(7):2081-2096. PubMed ID: 37151877
[TBL] [Abstract][Full Text] [Related]
15. Checkpoint kinase 2 (Chk2) supports sensitivity to platinum-based treatment in high grade serous ovarian cancer.
Alkema NG; Tomar T; van der Zee AG; Everts M; Meersma GJ; Hollema H; de Jong S; van Vugt MA; Wisman GB
Gynecol Oncol; 2014 Jun; 133(3):591-8. PubMed ID: 24657486
[TBL] [Abstract][Full Text] [Related]
16. Correlation Between E-cadherin Immunoexpression and Efficacy of First Line Platinum-Based Chemotherapy in Advanced High Grade Serous Ovarian Cancer.
Miše BP; Telesmanić VD; Tomić S; Šundov D; Čapkun V; Vrdoljak E
Pathol Oncol Res; 2015 Apr; 21(2):347-56. PubMed ID: 25108408
[TBL] [Abstract][Full Text] [Related]
17. Individuality in FGF1 expression significantly influences platinum resistance and progression-free survival in ovarian cancer.
Smith G; Ng MT; Shepherd L; Herrington CS; Gourley C; Ferguson MJ; Wolf CR
Br J Cancer; 2012 Oct; 107(8):1327-36. PubMed ID: 22990650
[TBL] [Abstract][Full Text] [Related]
18. Multi-gene expression predictors of single drug responses to adjuvant chemotherapy in ovarian carcinoma: predicting platinum resistance.
Ferriss JS; Kim Y; Duska L; Birrer M; Levine DA; Moskaluk C; Theodorescu D; Lee JK
PLoS One; 2012; 7(2):e30550. PubMed ID: 22348014
[TBL] [Abstract][Full Text] [Related]
19. MiR-1294 confers cisplatin resistance in ovarian Cancer cells by targeting IGF1R.
Zhang Y; Huang S; Guo Y; Li L
Biomed Pharmacother; 2018 Oct; 106():1357-1363. PubMed ID: 30119207
[TBL] [Abstract][Full Text] [Related]
20. Transcriptional epigenetic regulation of Fkbp1/Pax9 genes is associated with impaired sensitivity to platinum treatment in ovarian cancer.
Soto JA; Rodríguez-Antolín C; Vera O; Pernía O; Esteban-Rodríguez I; Dolores Diestro M; Benitez J; Sánchez-Cabo F; Alvarez R; De Castro J; Ibanez de Cáceres I
Clin Epigenetics; 2021 Aug; 13(1):167. PubMed ID: 34454589
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
